Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 6Terminated 3Unknown 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 29Carcinoma, Renal Cell 17Liver Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Carcinoma 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Breast Neoplasms, Male 2Blast Crisis 2Adenocarcinoma, Follicular 2Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1

Interventions

Carboplatin 7Pemetrexed 5pembrolizumab 4Gemcitabine 4osimertinib 3Sorafenib 3Paclitaxel 3Interleukin-2 3Cyclophosphamide 3Cisplatin 3seocalcitol 2selinexor 2patritumab 2liposomal doxorubicin 2interferon gamma-1b 2fludarabine 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Irinotecan 2Erlotinib Hydrochloride 2DNA 2Celecoxib 2Capecitabine 2Bleomycin 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2volociximab 1thioredoxin reductase inhibitor AM12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Carcinoma × Sorafenib × Clear all
NCT02323906 2017-03-20

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

Celgene

Phase 1 Terminated
12 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms

NCT00576056 2017-02-15

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

University of Pittsburgh

Phase 2 Terminated
19 enrolled 7 charts
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡